Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22 USD | -0.86% | +4.66% | -14.54% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The company's profit outlook over the next few years is a strong asset.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-14.54% | 590M | - | ||
+15.23% | 78.65B | A | ||
+9.32% | 8.94B | A- | ||
-10.76% | 5.16B | A- | ||
+54.31% | 4.85B | - | ||
+11.19% | 4.19B | B- | ||
-22.37% | 2.32B | C- | ||
+11.98% | 2.29B | B | ||
-30.09% | 2.19B | - | ||
+20.63% | 2.19B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- CALTX Stock
- CALT Stock
- Ratings Calliditas Therapeutics AB